Roche Secures Promising Bowel Disease Therapy--Which Could Help Treat Crohn's--In $7.1 Billion Telavant Deal

The Swiss pharma giant said it will begin late-stage trials on the experimental antibody therapy "as soon as possible" to help bring it to patients suffering from inflammatory bowel disease.